甲孕酮改善中晚期恶性肿瘤营养状况的临床观察

目的 明确甲孕酮联合化疗对于改善中晚期恶性肿瘤患者营养状况的改善情况，明确其对癌性恶病质的治疗作用以及用药时间与疗效的关系。方法123例接受全身静脉化疗的中晚期恶性肿瘤患者，采用单盲随机分组方法分为甲孕酮组和对照组。结果在甲孕酮组中，31．7％患者用药6周后体重增加，36．5％患者用药12周后体重增加；42．9％患者在用药6周食欲增加，58．7％患者在用药12周后食欲增加；33．3％患者用药6周后KPS评分增加，38．1％患者用药12周后KPS评分增加；15．9％患者用药6周后血清白蛋白值增加，31．7％患者用药12周后血清白蛋白值增加，与对照组相比均有显著性差异，用药时间与疗效成正比。同时甲孕酮组患者在化疗期间胃肠道反应的发生率及严重程度与对照组相比均有显著性差异。结论甲孕酮长期联合化疗对于改善中晚期恶性肿瘤患者的营养状况有明确的疗效，毒副作用小，可以用于癌性恶病质的治疗。

Observation on efficacy of medroxyprogesterone acetate in patients with advanced malignant tumor

Objective To investigate the effet of medroxyprogesterone acetate (MPA) on patients with advanced cancer. Methods All 123 patients with advanced malignant tumor with chemotherapy were randomly divided into two groups: 63 patients were treated with MPA and chemotheraphy, and the other 60 patients with chemotheraphy only as control. Results The results showed that the patients who were given MPA and chemotheraphy had weight gain(31.7%/6 weeks and 36.5%/12weeks),increasing intake of food (42.9%/6 weeks and 58.7%/12 weeks), Karnofsky`s score improvement in 33.3%/6 weeks,38.1%/12 weeks,blood albumin rising (15.9%/ 6weeks,31.7%/12weeks) ,and the level of gastroinestinal irritation was lower than the control group (P<0.05). Conclusion Chemotheraphy and MPA can improve the nutritional status of patients with middle and advanced malignant tumor.